9168 RESULTS
COMMENT The recent work of Minhas and colleagues unveils the crucial role of myeloid prostaglandin EP2 signaling in the bioenergetic dysfunction processes that occur during aging. The authors demonstrated that in aged mice, both central and peripheral inhibition ...
COMMENT For decades, cognitive deterioration occurring during aging was considered to be neuronal-centric, and thus was attributed solely to neuron exhaustion, dysfunction, or, in the extreme case, to neuronal loss. Over the last two decades, emerging studies ...
COMMENT This manuscript adds to the growing body of work supporting antibody-mediated agonism of TREM2 as a therapeutic approach for treatment of Alzheimer’s disease. These results are consistent with other studies demonstrating the impact of distinct TREM2 ...
COMMENT We thank Drs. Haass and Schlepckow for their comment. We agree that TREM2 agonist antibodies have been developed by other groups, an excellent body of work that we referenced and discussed in our paper. We would like to emphasize several points: First, ...
COMMENT This report is intriguing and reinforces the power of single-nucleus studies of human postmortem brain tissue for understanding neurodegenerative disease. The identification of RORB as a possibly critical protein associated with selective vulnerability ...
COMMENT In Alzheimer’s disease, which is so complex, selective cellular vulnerability is a key anchoring point for mechanistic discovery. To leverage it, we must understand what differs between vulnerable and spared cells as disease progresses. Single-nuclear RNA ...
COMMENT I believe the key element for all three antibodies that reduce PET amyloid is that they evade being bound up by monomers and can get sufficient antibody onto the plaques. This is true for BAN2401/lecanemab, aducanumab, and now donanemab. Other Aβ monomer ...
COMMENT We appreciate Helen Santoro’s thorough summary. We are writing to clarify comments attributed to Christian Haass that may not have considered the totality of key data upon which we base our conclusions: (1) In paragraph 10, Haass is quoted as saying “…nor ...
COMMENT In the current study the Colonna lab describes very similar properties of a new TREM2 agonistic antibody as in their previous paper using the Alector antibody AL002c which binds to the stalk region of TREM2 (Wang et al., 2020). To us, it looks like hT2AB ...
COMMENT Using longitudinally collected blood samples and data from the ADNI study from over 1,000 participants, Moscoso et al. evaluate the performance of p-tau181 as a biomarker of neurodegeneration and provide NfL for comparison. In the cognitively impaired ...
COMMENT The study by Moscoso and colleagues adds to the ongoing literature demonstrating that plasma p-tau181 is a sensitive and specific marker for Alzheimer’s disease (AD) pathology and clinical diagnosis. This study, using ADNI data, nicely highlights the ...
COMMENT In my opinion, this is the clearest indication that Alzheimer's disease is not a single entity, despite the ubiquity of amyloid plaques, and should not be treated as one. Therapies that seek to slow progression of dementia are unlikely to be ...
COMMENT Biological heterogeneity of Alzheimer’s disease is a relatively unexplored territory, even though there is ample evidence based on clinical and imaging studies that heterogeneity does exist. Here, Neff and colleagues explored heterogeneity in gene ...
COMMENT Kim et al. applied an elegant evolution-based variant functional impact weighting method and a novel discordant phenotype subsampling approach to identify genes that modify predicted AD outcomes in APOE-ε4 and ε2 carriers. Their analyses suggest ...
COMMENT In frontotemporal dementia, tau and TDP43 rarely appear together. People with #FTLD-TDP and TMEM106B polymorphism A/A have an odds ratio of 13.9 (crude) or 31.3 (multivariate) to develop a distinct 4R tauopathy. We investigated 90 FTLD-TDP cases—all types ...
